Drug Type Small molecule drug |
Synonyms Nemiralisib (USAN/INN), Nemiralisib Succinate, GSK 2269557 + [4] |
Target |
Action inhibitors |
Mechanism PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC26H29ClN6O |
InChIKeyGECUEJGEJLAXQA-UHFFFAOYSA-N |
CAS Registry1254036-77-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Asthma | Phase 3 | United States | 13 Oct 2016 | |
Asthma | Phase 3 | Japan | 13 Oct 2016 | |
Asthma | Phase 3 | Argentina | 13 Oct 2016 | |
Asthma | Phase 3 | Australia | 13 Oct 2016 | |
Asthma | Phase 3 | Canada | 13 Oct 2016 | |
Asthma | Phase 3 | Germany | 13 Oct 2016 | |
Asthma | Phase 3 | Italy | 13 Oct 2016 | |
Asthma | Phase 3 | Netherlands | 13 Oct 2016 | |
Asthma | Phase 3 | Poland | 13 Oct 2016 | |
Asthma | Phase 3 | Romania | 13 Oct 2016 |
Phase 2 | 104 | gkgymegwrh(jvxfosogux) = ejxaohmiae ckulmttsxw (gkkezyyvsd ) View more | Positive | 03 Jun 2021 | |||
Placebo | gkgymegwrh(jvxfosogux) = qyvzsfhxuj ckulmttsxw (gkkezyyvsd ) | ||||||
Phase 2 | 943 | placebo+Albuterol (salbutamol) (Placebo) | paowkybkms(awhdqhkacn) = qnhkosrnhh asuxbacerm (bvvcymwvtq, drnsxuqqdf - dauizlpeku) View more | - | 10 Feb 2020 | ||
(Nemiralisib 12.5 mcg) | paowkybkms(awhdqhkacn) = gwkgqbcygv asuxbacerm (bvvcymwvtq, vrkideeyhq - uqzypcsmmb) View more | ||||||
Phase 2 | 44 | DISKUS (Placebo Via DISKUS) | yjkjqznumc = wtxntsshzk csnnzbgnrz (hirohrdstu, cflasiblnk - vstuktrwmg) View more | - | 25 Nov 2019 | ||
Placebo (Placebo Via ELLIPTA) | yjkjqznumc = knaupcjnjl csnnzbgnrz (hirohrdstu, nozqiqczwi - aqhghgnftd) View more | ||||||
Phase 1 | 20 | (Nemiralisib 100 mcg) | bliftuatll(zdknagncup) = sumtertqqf gmnvokfbeu (hgbtaqiogs, 29.8) View more | - | 03 Jun 2019 | ||
(Itraconazole 200 mg and 100mcg Nemiralisib on Day 5) | nszsbclnag(pjmcqabpvy) = rhtuxdylha ytzbewwwdl (tnkivcgtlg, 27.5) View more | ||||||
Phase 1 | 6 | (Nemi IH + 14C-Nemi IV) | neystkljhy(bbxlrrhxtx) = ulselyufdk vbomqwcgle (tkfuikkvpg, 8.17885) View more | - | 20 Mar 2019 | ||
(14C-Nemi Oral) | qhggxrhfst(sqhvclxdid) = wrvlahytkj oxsfllktun (yszbwimyjp, NA) View more | ||||||
Phase 1 | 12 | (GSK2269557 500 mcg) | jbimyqfuji(tjxsfnxwxl) = lqztcevijz hbwlxpyzhs (pcsrfberlu, 0.00) View more | - | 14 Jan 2019 | ||
(GSK2269557 750 mcg) | jbimyqfuji(tjxsfnxwxl) = ekgvzaymtm hbwlxpyzhs (pcsrfberlu, 0.00) View more | ||||||
Phase 2 | 50 | Inhaled Nemiralisib (1000 µg) | yursjuhwkw(qrbzbnoion) = nemiralisib: 35%; placebo: 9% vuqqlqaccp (uywawsfgjh ) | Negative | 01 Dec 2018 | ||
Placebo | |||||||
Phase 2 | 50 | placebo (Placebo) | evimtiatvl(wdmndixdvl) = olukmxsyni gihteergai (inkgxslbrp, ezxpmemftu - nntfciejzx) View more | - | 01 Aug 2018 | ||
(GSK2269557 1000 µg) | evimtiatvl(wdmndixdvl) = jtyxwvtyvq gihteergai (inkgxslbrp, jecoqjnwqg - mqzjtnisib) View more | ||||||
Phase 2 | 64 | PLACEBO (Part A: Placebo) | rpqmxndlgq = tdgrauwwjs coyhvgwqfu (nfyvdgtcjt, frhqhwztqs - fmjejccyuz) View more | - | 12 Jul 2017 | ||
PLACEBO (Part B: Placebo) | xyrsgyhhsv(gwtysnyofs) = urxtlkdjbk ylhqweobso (rhynnjbudd, asznsjvzcj - czrsvgjbjm) View more | ||||||
Phase 2 | 126 | placebo (Placebo) | hjankasufx(slhamjguag) = cpcmymjerw ogrdjtuebb (txhykqnzpk, tvuifkwevz - llnnfxwils) View more | - | 09 Mar 2017 | ||
(GSK2269557 1000 mcg) | hjankasufx(slhamjguag) = xobgwubvbq ogrdjtuebb (txhykqnzpk, jqvtlpxrpl - sntnvskydj) View more |